In the era of precision oncology, AKT represents an attractive therapeutic target for the discovery of pathway-based targeted therapies selectively hitting cancer cells characterized by aberrant activation of PI3K/AKTs/mTOR signaling pathway. This evidence concerns the gene MTOR and cancer.